#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15242	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2577	730.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1694	1694	C	901	C,A,T	898,2,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15242	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2577	730.5	0	HET	.	.	.	C260T,A	.	260	260	C	770	770	C	902	C,T,A	712,188,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24672	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4221	729.0	0	.	n	.	0	T695C	SNP	695	695	T	1415	1415	C	969	C,T,G	962,4,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24672	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4221	729.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	2057	2057	A	1039	A,C	1038,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24672	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4221	729.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2691	2691	C	857	C,T,G	855,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24672	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4221	729.0	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3317	3317	T	777	T,G	775,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24672	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4221	729.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2765	2765	A	785	A,C	783,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2226	folP	852	852	100.0	folP.l15.c4.ctg.1	2001	138.6	1	SNP	p	R228S	1	.	.	682	684	AGC	1244	1246	AGC	251;253;252	A;G;C	251;253;252	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4944	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3787	162.8	1	SNP	p	S91F	0	.	.	271	273	TCC	793	795	TCC	177;177;176	T;C;C,A	177;177;175,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4944	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3787	162.8	1	SNP	p	D95N	0	.	.	283	285	GAC	805	807	GAC	182;182;181	G;A,G;C	182;181,1;181	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4944	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3787	162.8	1	SNP	p	D95G	0	.	.	283	285	GAC	805	807	GAC	182;182;181	G;A,G;C	182;181,1;181	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	1938	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1784	135.4	1	SNP	p	G45D	1	.	.	133	135	GAC	742	744	GAC	228;229;232	G;A;C	228;229;232	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1108	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1627	85.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5110	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3425	185.8	1	SNP	p	D86N	0	.	.	256	258	GAC	785	787	GAC	218;215;211	G;A;C	218;215;211	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5110	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3425	185.8	1	SNP	p	S87I	0	.	.	259	261	AGT	788	790	AGT	213;213;214	A,G;G;T,A	212,1;213;213,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5110	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3425	185.8	1	SNP	p	S87R	0	.	.	259	261	AGT	788	790	AGT	213;213;214	A,G;G;T,A	212,1;213;213,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5110	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3425	185.8	1	SNP	p	S87W	0	.	.	259	261	AGT	788	790	AGT	213;213;214	A,G;G;T,A	212,1;213;213,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5110	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3425	185.8	1	SNP	p	S88P	0	.	.	262	264	TCC	791	793	TCC	215;215;217	T,G;C,A;C,G	214,1;214,1;216,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4318	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3099	174.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1806	1808	GGC	268;261;262	G,A,T;G,T;C,G	266,1,1;260,1;261,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3792	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2976	158.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1526	1528	GCA	249;248;250	G;C;A	249;248;250	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3792	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2976	158.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1529	1531	ATC	250;251;248	A,C;T;C,T	249,1;251;247,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3792	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2976	158.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1541	1543	GTG	249;250;248	G;T;G	249;250;248	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3792	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2976	158.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1541	1543	GTG	249;250;248	G;T;G	249;250;248	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3792	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2976	158.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2045	2047	ACC	232;232;232	A;C;C	232;232;232	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3792	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2976	158.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2099	2101	GCG	223;220;217	G;C;G	223;220;217	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3792	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2976	158.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2099	2101	GCG	223;220;217	G;C;G	223;220;217	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3792	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2976	158.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2222	2224	GGC	214;213;214	G;G,T;C	214;211,2;214	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3792	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2976	158.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2231	2233	GGC	213;212;212	G;G;C,A	213;212;211,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3792	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2976	158.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2249	2251	CCG	204;206;201	C,G,A;C;G,A	202,1,1;206;200,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5496	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	3437	199.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2450	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2301	132.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	825	825	C	176	C	176	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	272	porB1a	984	287	90.72	porB1a.l6.c30.ctg.1	1048	24.9	0	.	p	.	0	H217N	NONSYN	649	651	CAT	784	786	AAT	2;2;2	A;A;T	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	272	porB1a	984	287	90.72	porB1a.l6.c30.ctg.1	1048	24.9	0	.	p	.	0	D218N	NONSYN	652	654	GAT	787	789	AAT	2;3;3	A;A;T	2;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	272	porB1a	984	287	90.72	porB1a.l6.c30.ctg.1	1048	24.9	0	.	p	.	0	A222V	NONSYN	664	666	GCT	799	801	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	272	porB1a	984	287	90.72	porB1a.l6.c30.ctg.1	1048	24.9	0	.	p	.	0	V226A	NONSYN	676	678	GTA	811	813	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	272	porB1a	984	287	90.72	porB1a.l6.c30.ctg.1	1048	24.9	0	.	p	.	0	.	MULTIPLE	700	702	ACT	834	836	GTA	1;1;1	G;T;A	1;1;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	272	porB1a	984	287	90.72	porB1a.l6.c30.ctg.1	1048	24.9	0	.	p	.	0	N237fs	FSHIFT	709	709	A	843	843	A	1	A	1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	G38E	NONSYN	112	114	GGA	490	492	GAA	229;230;230	G;A;A	229;230;230	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	E48G	NONSYN	142	144	GAA	520	522	GGA	229;231;233	G,T;G,T;A	228,1;230,1;233	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	T87A	NONSYN	259	261	ACT	637	639	GCT	199;197;196	G,A;C;T	198,1;197;196	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	T89S	NONSYN	265	267	ACC	643	645	AGC	192;193;193	A;G,C;C	192;192,1;193	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	.	MULTIPLE	358	359	AA	735	736	CG	211;209	C;G	211;209	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	.	MULTIPLE	361	362	GA	738	740	CAG	207;210;213	C;A,G;G,C	207;209,1;212,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	N122K	NONSYN	364	366	AAC	742	744	AAA	216;219;220	A,C;A;A,G	215,1;218;218,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	K143E	NONSYN	427	429	AAA	805	807	GAA	218;217;222	G,A;A;A	216,2;217;222	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	V151A	NONSYN	451	453	GTA	829	831	GCA	237;237;237	G;C;A	237;237;237	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	N212D	NONSYN	634	636	AAT	1012	1014	GAT	204;203;206	G;A;T	204;203;206	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	D213G	NONSYN	637	639	GAT	1015	1017	GGT	203;201;199	G,C;G,A;T,A	202,1;200,1;198,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1030	1032	ATG	199;199;200	A,C;T,A;G,A	198,1;198,1;199,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1144	1146	GCA	222;222;222	G;C;A	222;222;222	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1147	1149	ACG	225;223;224	A;C;G	225;223;224	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	R258G	NONSYN	772	774	CGT	1150	1152	GGG	224;224;224	G;G,T,A;G	224;222,1,1;224	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1153	1155	GTT	226;224;225	G;T,A;T,G	226;223,1;224,1	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1213	1215	GTA	225;223;220	G,T;T,G;A	224,1;222,1;220	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1252	1254	ACT	211;212;215	A;C;T	211;212;215	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1258	1260	GAT	220;222;222	G;A;T	220;222;222	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1270	1272	CAC	234;233;234	C;A,T;C	234;232,1;234	.	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	1	SNP	p	G120K	1	.	.	358	360	AAG	735	737	CGG	211;209;207	C;G;G	211;209;207	porB1b.WHO_Z_02266c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	1	SNP	p	A121D	1	.	.	361	363	GAC	738	741	CGC	207;213;214	C;G,C;CAAA,CAA	207;212,1;210,1	porB1b.WHO_Z_02266c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Z_02266c	porB1b.WHO_Z_02266c	1	1	539	2614	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1565	200.3	1	SNP	p	D121N	0	.	.	361	363	GAC	738	741	CGC	207;213;214	C;G,C;CAAA,CAA	207;212,1;210,1	porB1b.WHO_Z_02266c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9536	rpoB	4179	4179	100.0	rpoB.l6.c17.ctg.1	5336	222.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2297	2299	AAT	252;251;253	A,G,T;A;T,G	250,1,1;251;252,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1384	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1466	117.9	1	SNP	p	V57M	1	.	.	169	171	ATG	748	750	ATG	246;245;242	A;T;G	246;245;242	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
